We recently published a list of 10 Worst High-Risk High-Reward Growth Stocks To Buy. In this article, we are going to take a ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PTC Therapeutics (PTCT – Research Report) and ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $69.89, with a ...

Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) had its target price increased by Needham & Company LLC from $64.00 to $66.00 in a research note released on Tuesday, Marketbeat reports. Needham & ...

Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The company had revenue of $41.83 million for the quarter, compared to the consensus ...

Needham analyst Joseph Stringer maintained a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report) today and set a price target of ...

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced ...

Rhythm Pharmaceuticals, Inc. has announced a collaboration with the Raymond A. Wood Foundation to conduct research on the impact of fatigue in individuals diagnosed with craniopharyngioma ...

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the ...

Milestone Pharmaceuticals said on Friday the U.S. health regulator had declined to approve its nasal spray to treat a type of ...